Inorganic Compounds Going NANO
- 1. Department of Life Sciences, New University of Lisbon, Portugal
Transition-metal complexes have shown significant anti-tumour potential and have advanced towards clinical trials. However, tumour cells often develop resistance to chemotherapeutics, which couple to the inherent compound’s’ toxicity and solubility hampers their translation to the clinics. Therefore, besides the tremendous efforts to synthesise and characterise novel compounds, it is essential to create new drug delivery systems that circumvent these problems, allowing specific and selective delivery of drugs to tumour cells, thus decreasing the required dose and reducing side effects to the healthy tissue. Nano biotechnoloy has been providing for innovative solutions to address this challenge, via the smart design of nano formulations suitable for targeted delivery to the tumour microenvironment. In this review, we discuss recent nano systems combined with medicinal chemistry in cancer therapeutics, focusing on the clinical translation of such systems.
Coimbra J, Mota C, Santos S, Baptista PV, Fernandes AR (2015) Inorganic Compounds Going NANO. Ann Med Chem Res 1(2): 1010.
• Cancer therapy
• Inorganic compounds
• Metal complexes
• Drug delivery
The discovery of cisplatin by Rosenberg and colleagues in 1965 was a landmark on the use of inorganic metal complexes as chemotherapeutic agents in cancer . One of the major areas of medicinal chemistry is the application of inorganic compounds, or molecules bound to a metal centre, to cancer therapy (for a review see [2-4]). However, inorganic compounds toxicity in tumour adjacent or distant healthy cells is usually high due to the lack of specificity. There is, therefore, a need for new drugs with an improved spectrum of efficacy and lower toxicity. Also, there has been an increasing concern related to the surge of multidrug resistance (MDR) by cancer cells. Resistance to treatment may be acquired or intrinsic, both entailing treatment failure . Despite the translation of platinum based metal complexes to clinical practice and their wide application in treatment of several types of tumours (e.g breast cancer) , in the last few years, efforts have been made for improving the efficacy of inorganic compounds and reduce their side effects. Such developments have included the use of nanobiotechnology towards targeted nanovectorization systems, bypassing biological barriers and delivery the drug directly to target cells in therapeutic concentrations, whilst sparing the healthy tissues to the deleterious effect of such chemical compounds .
In this review we intend to address the main mechanism of action of platinum- and non-platinum based metal compounds, already FDA approved, in clinical or pre-clinical phases as well as problems that still have to be addressed. The combination of the most promising metal compounds with the rising benefits of nanobiotechnology could be the future of cancer therapy.
INORGANIC METAL COMPOUND IN CANCER THERAPY
Metals and mode of action
Following the success of cisplatin as an antitumor agent, several other complexes containing platinum or other metals such as ruthenium, gold, titanium, copper, iron, rhodium, vanadium, and cobalt have been proposed with less toxicity and selectivity towards tumour cells . A punctual change in metallic centre, oxidation state, ligands, geometry or even in coordination number, lead to different reactivity, affecting the drug’s mechanism of action , such as disturbance of cellular redox homeostasis . For a more complete review on synthesis directions towards the understanding of various transition metals compounds used in biomedical applications please see [3,4,11-13].
The metal may have a functional or a structural role, acting as an in vivo carrier for active ligands or as in vivo catalyst or behave as photosensitizer ; they coordinate ligands in three dimension configuration, allowing functionalization with groups designed for specific molecular targets. Despite the high number of promising metal complexes candidates in (pre) clinical studies [15-17], only a few number of metal complexes have been translated to clinical phase I and phase II studies so far [9,16].
Cisplatin is the most well-known and characterized anti tumour drug, binding to DNA purine bases, forming inter-and intra-strand DNA adducts that ultimately induce apoptosis [18,19]. More recently, Oxaliplatin, the first FDA-approved drug with similar therapeutic results as cisplatin, has been used as substitute of cisplatin with no expressive acquisition of multidrug resistance due to an immunogenic response dependent of the toll-like receptors [19,20]. Satraplatin, another platinum compound in advanced clinical trial phases, is another potential candidate for cancer therapy that, by being more lipophilic, shows improved pharmacokinetic properties. Another advantage is that satraplatin-induced adducts are not recognized by DNA mismatch repair proteins, which decreases the potential surge in resistance [21,22].
Non-platinum metal compounds, a promising future – Ruthenium, Titanium and Gallium
Despite almost 50% of chemotherapy treatments include platinum compounds , other transition metals show antitumour potential and are already in clinical trials.
Ruthenium appears to be the next transition-metal to translate to the clinics due to specific properties, such as:i) the ability to promote exchanges between a O- and N-donor molecules identic to platinum drugs; ii) the octahedral geometry allowing binding to nucleic acids; iii) may exist in different oxidation states (from II to IV) in biological fluids; iv) in the oxidation state III gives rise to a low reactive pro-drug that can be activated selectively in solid tumours due to its reducing environment (low oxygen content), and v) it is transported to tumour cells by transferrin . This last intrinsic characteristic allows the use of cell mechanism of iron transport allowing reduction of its toxicity . In general, ruthenium complexes inhibit DNA replication, and induce mutations via activation of reactive oxygen species (ROS) and reduction of RNA synthesis. Similarly to platinum, the biggest interest in ruthenium is the ability to bind to DNA . NAMI-A and KP1019 consist of two ruthenium (III) complexes that already achieved phase I and II clinical trials, respectively . NAMI-A has selective effect on metastases (particularly lung metastasis) of solid metastasizing tumours, with no associated effect on primary tumour growth but has evidenced some toxicity in pre-clinical studies .Despite these toxicity effects (increase creatinine levels in kidneys; histological lesions of glomeruli and tubuli; increased spleen volume with lymphocytic depletion; increase of circulating lymphocytes; alterations of mitochondrial membranes) NAMI-A is currently studied for its application as a second line therapy in the metastatic non-small cells lung cancer after Gemcitabine therapy [28,29].
KP1019 revealed direct antitumour activity after entering the cell through binding to transferrin, by inducing apoptosis via the mitochondrial pathway and also generates ROS and dose dependent toxicity proved to be limited or even in existent . KP1019 has already completed phase I clinical trials with promising results although there were some solubility problems, a reason why NKP-1319, a more soluble analogue has recently entered phase I clinical trials [28,30].
Titanium is a metal biologically compatible that can lead to non-toxic anticancer drugs. Actually, it was the second metal to go to clinical trials, using Ti (IV) species that binds covalently to DNA . Budotitane, a titanium inorganic complex, followed platinum in clinical trials, as a result of proved antitumour activity in colon tumour cells. However, the instability of Ti (IV) compounds in solution due to a rapid hydrolysis at physiological conditions resulted in an insoluble TiO2 and the loss of antitumour properties leading to disappointed results in phase I clinical trials . Recently, a new class of titanium (IV) complexes, titanium salan complexes, proved to have a higher antitumour activity and hydrolytic stability .
Gallium, due to the similarity to ruthenium is able to complex with proteins and ligands that bind iron and may be transported using iron bio-distribution pathways . Gallium nitrate is the first-generation of gallium anticancer compounds, capable to induce apoptosis through activation of Bax, releasing cytochrome c from the mitochondria and activating effector caspases. Phase I and II clinical trials have attested their activity in lymphomas. Unfortunately, malignant cells showed some resistance to this drug and a high level of gallium in plasma associated to kidney toxicity, demonstrated severe dose limitations [34,35].
Why going NANO?
The indiscriminate destruction of healthy cells, the toxicity of conventional chemotherapeutic agents, as well as the development of MDR, support the need to find new effective targeted therapies based on the heterogeneity of the tumour cells . Nanomedicine is a promising and thriving field that applies nanotechnology to medicine, and in particular nanoparticles (NPs) have been successfully applied as drug carriers, in hyperthermia or radiotherapy, photodynamic therapy and photo thermal microscopy [37,38]. The use of nano-sized materials has several benefits like high surface/volume ratios, modifiable structures and adaptable sizes , which enhance the potential of nanoparticles as drug carriers either via the enhanced permeability and retention effect (EPR effect) due to tumour vasculature and impaired lymphatic system - passive targeting; or actively targeted to cancer cells via functional moieties grafted to the surface [37,40]. Twenty years after Doxil®, the first FDAapproved nano-drug, and less than five years from Abraxane(®), the novel nanoparticle albumin-bound [nab] paclitaxel approved for the treatment of metastatic breast cancer by FDA, there is still a long way towards active drug targeting which allows drug release at the tumor site to improve efficacy and reduce the dose dependant toxicity of chemicals (for a review see [36,41- 43]). These novel targeted therapies because of their potential for multi-functionality aims at simultaneously block tumour cell transduction pathways and/or specific proteins to foster cancer cell death while deliver common and already prove as effective inorganic metal compounds specifically to cancer cells, minimizing the undesirable side effects leading to a new era of personalized medicine [36,43].
An increasing number and diversity of nano particles have been proposed as vectorisation vehicles, ranging from polymer-based nano particles to dendrimers, lipid-based nano particles, ceramic nanoparticles, metal nano particles and carbon nanotubes . Table 1 illustrates recent examples of nanovectorized drugs according to nano particle category. Current studies on nanovectorized compounds are comprised mostly of FDA-approved compounds or well characterized drugs as a result of the profound knowledge of the compounds in terms of mechanisms of action, pharmacokinetic and pharmacodynamic properties as well as physic-chemical characteristics.
Conclusions and future perspectives
Inorganic medicinal chemistry allied to nanotechnology has been providing a major help in cancer treatment. The right nano formulation can bypass biological barriers and deliver the drug directly to the cancer cell, allowing the decrease of drug dosage and avert the healthy cell from the dangerous side effects of chemotherapy . Nanodelivery systems may provide for improved vectorisation strategies but uptake by the liver and spleen seriously limits interaction with the target tissues and may therapeutic efficacy .
The great next step in nanodelivery for inorganic metal complexes is to combine intrinsic properties towards effective combinatory strategies to improve efficacy and reduce the dose dependant toxicity of chemicals. Another avenue of development is optimization of such systems for nanotheranostics, allowing disease progression monitorisation and therapeutic evaluation in real time [53,55]. Allowing a plan for each cancer treatment according to the patients individual responses, lowering the adverse side-effect and incorrect drug dosage would be some of the advantages of going nano.
Table 1: Nano vectorised FDA-approved inorganic compounds enclosing increased anticancer properties compared to free compound (2010-2015). Drug denomination, nano carrier and incorporated inorganic compound, applications, mechanism of action and pipeline status. * FDA-approved inorganic compounds with anti tumour properties.
|Drug denomination||Inorganic compound||Nanocarrier||Applications||Mechanism of action||Pipeline Status||Refs.|
|Oxaliplatin vectorized in chitosan nanoparticles||Oxaliplatin*||Chitosan NPs||Cytotoxicityin MCF7 cell line||pH dependent release behaviour||Pre-clinical (In vitro studies)|||
|Carboplatin vectorized in polymethylmethacrylateNPs||Carboplatin*||PolymethylmethacrylateNPs||Advanced intra-ocular retinoblastoma||Increases intra-ocular drug concentration||Pre-clinical (In vivo studies)|||
|PLA-NPs loaded with KP1019||KP1019||Poly lactic acid||Cytotoxicity in SW480 and Hep3B cell lines||Stabilizes free compound in water and increases cytotoxicity||Pre-clinical (In vitro studies)|||
|DOTAP loaded with AziRu||AziRu||Cationic lipid DOTAP||Cytotoxic effect in MCF7 and WiDr cell lines||Improved cytotoxicitycomparedto free AziRu||Pre-clinical (In vitro studies)|||
|Lipoplatin||Cisplatin*||Liposome||Pancreatic/ Head and Neck/ breast cancer||Combined with paclitaxel for chemotherapy in nonsmall cell lung cancer (NSCLC)||In clinical trials phase III|||
|Nanobins||Arsenic trioxide*||Liposome||Female lymphomas||Cytotoxicity in cancer cells and protective effect toovarian cells||Pre-clinical (In vivo studies)|||
|Cationic Liposomal ToThyCholRu||Ruthenium complex ( ToThyCholRu)||Liposome||Cytotoxicity in MCF7 and WiDrcell lines||Increased toxicity comparedfree ruthenium complex||Pre-clinical (In vitro studies)|||
|Cisplatin encapsulated in multi-walled carbon nanotube capped with functionalized gold NPs||Cisplatin*||Carbon nanotubes||Cytotoxicity in MCF7 cell line||Carbon nanotubes bottles. Increased cytotoxicity compared tofree cisplatin||Pre-clinical (In vitro studies)|||
We thank FCT/MEC for financial support (PTDC/BBBNAN/1812/2012; UID/Multi/04378/2013).
1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222: 385-386.
2. Muhammad N, Guo Z. Metal-based anticancer chemotherapeutic agents. Curr Opin Chem Biol. 2014, 19: 144-153.
3. Shaili E. Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments. Sci Prog. 2014; 97: 20-40.
4. Hu C, Li X, Wang W, Zhang R, Deng L. Metal-N-heterocyclic carbene complexes as anti-tumor agents. Curr Med Chem. 2014; 21: 1220- 1230.
5. Wang JQ, Zhang PY, Ji LN, Chao H. A ruthenium (II) complex inhibits tumor growth in vivo with fewer side-effects compared with cisplatin. J InorgBiochem. 2015; 146: 89-96.
6. Biersack B, Ahmad A, Sarkar FH, Schobert R. Coinage metal complexes against breast cancer. Curr Med Chem. 2012; 19: 3949-3956.
7. Conde J, Doria G, Baptista P. Noble Metal Nanoparticles Applications in Cancer. J Drug Deliv. 2012; 751075.
8. Martins P, Marques M, Coito L, Pombeiro AJL, Baptista PV, Fernandes AR. Organometallic Compounds in Cancer Therapy: Past Lessons and Future Directions. Anticancer Agents Med Chem. 2014; 14: 1199- 1212.
9. Romero-Canelón I, Sadler PS. Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation. Inorg Chem. 2013; 52: 12276-122791.
10. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal. 2011; 15: 1085-1127.
11. Colotti G, Ilari A, Boffi A, Morea V. Metals and metal derivatives in medicine. Mini Rev Med Chem. 2013; 13: 211-221.
12. Tan SJ, Yan YK, Lee PP, Lim KH. Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Med Chem. 2010; 2: 1591-1608.
13. Schmitt SM, Frezza M, Dou QP. New applications of old metal-binding drugs in the treatment of human cancer. Front Biosci (Schol Ed). 2012; 4: 375-391.
14. Gianferrara T, Bratsos I, Alessio E. A categorization of metal anticancer compounds based on their mode of action. Dalton Trans. 2009; 37: 7588-7598.
15. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. From bench to bedsi?de--preclinical and early clinical development of the anticancer agent indazolium trans- [tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J InorgBiochem. 2006; 100: 891-904.
16. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim). 2007; 340: 117-126.
17. Kostova I. Gold coordination complexes as anticancer agents. Anticancer Agents Med Chem. 2006; 6: 19-32.
18. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31: 1869-1883.
19. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010; 39: 8113-8127.
20. Kono K, Mimura K. Immunogenic tumor cell death induced by chemo radiotherapy in a clinical setting. Oncoimmunology. 2013; 2: 22197.
21. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, et al. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. ClinGenitourin Cancer. 2011; 9: 27-30.
22. Akshintala S, Marcus L, Warren KE, Murphy RF, Sissung TM, Srivastava A, et al. Phase 1 trial and pharmacokinetic study of the oral platinum analogsatraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatr Blood Cancer. 2015; 62: 603- 610.
23. Schiesser S, Hackner B, Vrabel M, Beck W, Carell T. Synthesis and DNADamaging Properties of Cisplatin-N-Mustard Conjugates. Eur. J. Org. Chem. 2015; 2015: 2654–2660.
24. Bergamo A, Gaiddon C, Schellens JHM, Beijnen JH, Sava G. Approaching tumour therapy beyond platinum drugs: Status of the art and perspectives of ruthenium drug candidates. J InorgBiochem. 2012; 106: 90-99.
25. Porto H, Vilanova-Costa C, Mello F, Costa W, Lima A, Pereira F, et al. Synthesis of a ruthenium(II) tryptophan-associated complex and biological evaluation against Ehrlich murine breast carcinoma. Transition Met Chem. 2015; 40: 1–10.
26. Ramadevi P, Singh, R, Jana SS, Devkar R, Chakraborty, D. Ruthenium complexes of ferrocenemannich bases: DNA/BSA interactions and cytotoxicity against A549 cell line. J PhotochPhotobio A. 2015; 305: 1-10.
27. Clavel CM, P?unescu E, Nowak-Sliwinska P, Griffioen AW, Scopelliti R, Dyson PJ. Modulating the Anticancer Activity of Ruthenium (II)-Arene Complexes. J Med Chem. 2015; 58: 3356-3365.
28. Antonarakis ES, Emadi A. Ruthenium-based chemotherapeutics: are they ready for prime time?. Cancer ChemotherPharmacol. 2010; 66: 1-9.
29. Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, Werhoven E, et al. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs. 2015; 33: 201-214.
30. Trondl R, Heffeter P, Kowol CR, Jakupec MA, Berger W, Keepler BK. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chem. Sci. 2014; 5: 2925-2932.
31. Pages BJ, Ang DL, Wright EP, Aldrich-Wright JR. Metal complex interactions with DNA. Dalton Trans. 2015; 44: 3505-3526.
32. Ali A, Bhattacharya S. DNA binders in clinical trials and chemotherapy. Bio org Med Chem. 2014; 22: 4506–4521.
33. Glasner H, Tshuva EY. C1-Symmetrical Titanium (IV) Complexes of Salan Ligands with differently Substituted Aromatic Rings: Enhanced Cytotoxic Activity. Inorg. Chem. 2014; 53: 3170-3176.
34. Wu X, Wang TW, Lessmann GM, Saleh J, Liu X, Chitambar CR, Hwang ST. Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice. J Invest Dermatol. 2015; 135: 877-884.
35. Chitambar CR, Purpi DP, Woodliff J, Yang M, Wereley JP. Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J PharmacolExpTher. 2007; 322:1228-1236.
36. Pérez-Herrero E, Fernández-MedardeA. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015; 93: 52-79.
37. Cabral RM, Baptista PV. The Chemistry and Biology of Gold Nanoparticle-Mediated Photothermal Therapy: Promises and Challenges. Nano LIFE. 2013; 3: 1330001.
38. Zhang X. Gold Nanoparticles: Recent Advances in the Biomedical Applications. Cell Biochemistry and Biophysics. Cell BiochemBiophys. 2015.
39. Nikalje A. Nanotechnology and its applications in Medicine. Med Chem. 2015; 5: 81-89.
40. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012; 63: 185–198.
41. Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160: 117-134.
42. Montero AJ, Adams B, Diaz-Montero CM, Glück S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev ClinPharmacol. 2011; 4: 329-334.
43. Ediriwickrema A, Saltzman WM. Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. ACS BiomaterSci Eng. 2015; 1: 64-78.
44. Martins P, Rosa D, Fernandes AR, Baptista PV. Nanoparticle Drug Delivery Systems: Recents Patents and Applications in Nanomedicine. Recent Pat Nanomed. 2014; 3: 105-118.
45. Vivek R, Thangam R, Nipunbabu V, Ponraj T, Kannan S. Oxaliplatinchitosan nanoparticles induced intrinsic apoptotic signaling pathway: A “smart” drug delivery system to breast cancer cell therapy. Int. J. Biol. Macromol. 2014; 65: 289–297.
46. Shome D, Kalita D, Jain V, Sarin, R, Maru GB Bellare JR. Carboplatin loaded polymethylmethacrylatenano-particles in an adjunctive role in retinoblastoma: An animal trial. Indian J. Ophthalmol. 2014; 62: 585–589.
47. Fischer B, Heffeter P, Kryeziu K, Gille L, Meier SM, Berger W, et al. Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton Trans. 2014; 43: 1096–1104.
48. Mangiapia G, Vitiello G, Irace C, Santamaria R, Colonna A, Angelico R, et al. Anticancer Cationic Ruthenium Nanovectors: From Rational Molecular Design to Cellular Uptake and Bioactivity. Biomacromolecules. 2013; 14: 2549–2560.
49. Pillai G. Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. SOJ Pharm Pharm Sci. 2014; 1: 13.
50. Ahn RW, Barret SL, Raja MR, Josefik JK, Spaho L, Chen H, et al. NanoEncapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In vitro and In vivo. PLoS ONE. 2013; 8: 4–13.
51. Vitiello G, Luchini A, D’Errico G, Santamaria R, Capuozzo A, Irace C, et al. Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex. J. Mater. Chem. B. 2015; 3: 3011-3023.
52. Li J, Yap SQ, Yoong SL, Nayak TR, Chandra GW, Ang WH, et al. Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin. 2014; 50: 1625–1634.
53. Baptista PV. Gold nanobeacons: a potential nanotheranostics platform. Nanomedicine. 2014; 9: 2247–2250.
54. Silva J, Fernandes AR, Baptista PV. Application of Nanotechnology in Drug Delivery. In: Sezer, AD, ed. Application of Nanotechnology in Drug Delivery. In Tech. 127-154.
55. Luk BT, Zhang L. Current Advances in Polymer-Based Nanotheranostics for Cancer Treatment and Diagnosis. ACS Appl. Mater. Interfaces. 2014; 6: 21859–21873.